Table 1: Characteristics of the study cohort with dilated cardiomyopathy ( ).

Age (years)55 (43–64)
Gender (m/f)56/22
Ejection fraction in %29.5 (20–45)
Left ventricular end-diastolic diameter (in mm)60 (52–66)
6-minute walk test (distance in m)503 (417–596)
Peak oxygen consumption (L/min/kg)17.6 (14.5–23)
NYHA class
 Class I36 (46.1%)
 Class II37 (47.4%)
 Class III5 (6.4%)
 Class IV0 (0%)
Medication
β-Blockers74 (94.9%)
 ACEI/AT antagonists77 (98.7%)
 Aldosterone antagonists41 (52.6%)
 Diuretics53 (67.9%)
 Glycosides23 (29.5%)
Diabetes6 (7.7%)
Creatinine (mg/dL)0.93 (0.8–1.2)
sTWEAK in pg/mL603 (423–839)
sCD163 in ng/mL2554 (1990–3479)
NT-proBNP in ng/L482 (211–1505)
Death/heart transplantation on 4-year follow-up4/1
Functional deterioration (≥1 NYHA class)41 (52.6%)
Functional deterioration (≥2 NYHA classes)11 (14.1%)

Values given as median (IR), number, or number (%).